Abstract
Purpose :
To study the safety and efficacy of PRN (pro re nata) ranibizumab in patients with naive DME (diabetic macular edema) in clinical practice in the Ophthalmology department of the HCUV (Hospital Clínico Universitario de Valladolid) and to study the relationship between diabetes’s systemic management, OCT (optical coherence tomography) biomarkers and patient’s evolution, in order to establish factors that may predict the response to treatment.
Methods :
Retrospective transversal study from patient records from patients under treatment with ranibizumab and PRN pattern in 2017 and their OCT images. Data were studied using descriptive and inferential analysis systems.
Results :
After treatment, all patients were stable or achieved better anatomical and functional outcomes. The mean number of letters gained of BCVA (best corrected visual acuity) was 5,77 ± 6,41 letters. The average number of injections was 4,53 ± 2,06 (under 7 recommended injections on the first year of treatment). There was a CMT (central macular thickness) decrease of 110,77 ± 93,95 μm. Macular volume had a beneficial evolution too: Basal macular volume was 9,71 ± 1,65mm3 and final macular volume was 8,43 ± 1,17mm3. There was no relationship between systemic factors and DME evolution. No safety issues were found. Higher values of initial CMT and DME volume were related to better anatomical evolution after treatment (p<0,05).
Conclusions :
Ranibizumab treatment with PRN pattern is effective for maintenance and improvement of visual function in DME. Patients with higher initial macular volume and higher CMT had better anatomical evolution after treatment. Alternatives for treatment and follow-up should be considered as injections and visits are below recommended values.
This is a 2020 ARVO Annual Meeting abstract.